ClinicalTrials.gg
RecruitingNCT06939660BASEGOUpdated May 20, 2025

BCI-Assisted SCS-EXS for Gait Optimization

An interventional study of BCI-SCS-EXS in Spinal Cord Injuries (SCI), Spinal Cord Injury, Chronic and Spinal Cord Injury, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
14 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Spinal Cord Injuries with a site in China — 26 open to participants now, 32 under way, none of them phase 3. Spinal Cord Injuries · China.

Planned enrollment
70th of 71
3 · median 36
Started
2025
with 12 others
No phase
44 of 80
22 open now
Primary completion
2026-05
later than 5 of 31 live
Registered
54th of 80
by date
Lead sponsor
6 of 80
Xuanwu Hospital, Beijing

Among the 80 studies in Spinal Cord Injuries with a site in China, this one is the 70th largest by planned enrollment of the 71 interventional ones that give a count, is one of 13 that started in 2025, is one of 44 with no phase, reaches primary completion later than 5 of the 31 other live ones, and was the 54th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

26 of the 80 studies in Spinal Cord Injuries with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 14 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Spinal Cord Injuries with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and technical feasibility of a novel brain-machine interface (BCI)-assisted spinal cord stimulation (SCS) and exoskeleton (EXS) system in patients with spinal cord injury (SCI). The primary aim is to determine whether the BCI-SCS-EXS system can safely and effectively improve lower limb motor function and quality of life in individuals with chronic SCI.

Participant Population:

Adults aged 14-65 years (sex/gender not limited). Patients with chronic SCI (≥6 months post-injury) classified as ASIA A, B, or C.

Individuals with stable health status, MMSE ≥22, and secondary education or above.

Primary Questions:

  1. Is the BCI-SCS-EXS system safe and technically feasible for SCI rehabilitation?
  2. Does the system improve lower limb motor function and quality of life in SCI patients?

Interventions:

Participants will undergo the following procedures:

Phase I (Implantation):

BCI implantation: ECoG electrodes placed over the motor cortex to decode lower limb movement intent.

SCS electrode implantation: 5-6-5 paddle electrodes at T11-L2 for targeted spinal cord stimulation.

Phase II (System Calibration):

BCI-SCS synchronization: Calibration of decoded motor intent to trigger SCS parameters.

SCS-EXO synchronization: Integration of SCS pulses with exoskeleton-assisted gait training.

Phase III (Rehabilitation):

Daily BCI-SCS-EXS training sessions (60 minutes, 5 times/week for 1 year). Adaptive adjustments to stimulation parameters and exoskeleton support based on performance.

Remote monitoring of device performance and emergency intervention for technical issues.

Outcome Measures:

Primary: Safety (adverse events, device performance, synchronization metrics). Secondary: Efficacy (motor function, neurophysiological function, quality of life).

Ethics and Safety:

Informed consent will be obtained from all participants. Adverse events will be monitored and reported according to CTCAE 5.0 guidelines.

Participant confidentiality will be strictly maintained. This study will provide foundational evidence for the safety and feasibility of the BCI-SCS-EXO system, paving the way for future randomized controlled trials in SCI rehabilitation.

03

Conditions studied

  • Spinal Cord Injuries (SCI)
  • Spinal Cord Injury, Chronic
  • Spinal Cord Injury
  • Spinal Cord Injury Cervical
  • Spinal Cord Injury Thoracic
  • Spinal Cord Injury (Quadraplegia)
  • Motor Impairment
  • Motor Deficits
  • Gait Training
  • Gait Impairment

Keywords

  • Brain-computer interface
  • Spianl cord stimulation
  • Exoskeleton
  • Rehabilitation
  • Spinal cord injury
  • Motor dysfunction
  • BCI
  • Brain-spinal interface
  • BSI
  • Brain-machine interface
  • Gait training
  • Neural plasticity
04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 14-65 years, any gender.
  • Clinical diagnosis of spinal cord injury (SCI) due to trauma, inflammation, tumor, vascular disease, or iatrogenic factors, confirmed by medical history, physical examination, and ancillary tests, resulting in lower limb motor dysfunction.
  • SCI diagnosed ≥6 months prior, with ≥1 month of continuous conventional rehabilitation (e.g., physical therapy, acupuncture, hydrotherapy, ≥3 hours daily) without significant improvement in motor function in the past 2 months.
  • ASIA Impairment Scale (AIS) grade A, B, or C based on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).
  • Good general health with a ≥12 months.
  • (MMSE) score ≥22.
  • Educational attainment of secondary school or above.
  • Willingness to participate, provide , and comply with study follow-up.

Exclusion criteria

Exclusion Criteria:

  • Presence of diseases other than spinal cord injury (SCI) that affect lower limb motor function, including brain diseases (e.g., brain tumor, stroke), lower limb vascular diseases (e.g., lower limb vascular occlusion), peripheral nerve diseases, or lower limb bone diseases (e.g., osteoarthritis, joint contracture).
  • Requires continuous medical interventions (e.g., tracheal intubation, nasogastric feeding) to maintain critical physiological functions (e.g., heartbeat, respiration, swallowing).
  • Congenital or acquired structural abnormalities of the lower limb bones or muscles.
  • Presence of surgical (e.g., anesthesia-related adverse reactions, coagulation risks, or surgeon's determination of unsuitability for surgery).
  • Presence of active implantable devices except for SCS or BCI devices (e.g., pacemakers, defibrillators, drug infusion pumps, cochlear implants, sacral nerve stimulators).
  • Unable to receive implantable devices due to other disease treatments or investigations, or requires magnetic resonance imaging (MRI) during the device implantation period.
  • MRI shows structural damage >50% in motor function areas (precentral and postcentral gyri, ventromedial sensorimotor areas, mid temporal lobe, Broca's area, Wernicke's area, Geschwind's area), or DTI shows damage >50% in the posterior limb of the internal capsule.
  • Severe cardiovascular disease: Above level II myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including ≥450 ms in men, ≥470 ms in women), level III-IV heart failure ( classification), or echocardiography showing \<50%.
  • Coagulation abnormalities ( >1.5 , PT >ULN +4 s, or APTT >1.5 ULN), hemorrhagic tendency, or undergoing thrombolytic or anticoagulant therapy.
  • Severe infections within 4 weeks before surgery (requiring IV antibiotics, antifungals, or antivirals) or lumbar soft tissue infections, or unexplained fever >38.5℃ during screening or before surgery.
  • infection, acquired immunodeficiency syndrome (AIDS), active tuberculosis, active (HBV DNA ≥500 IU/ml), (positive HCV antibody and detectable HCV-RNA), or co-infection of hepatitis B and C.

Severe cerebrovascular events (including , cerebral hemorrhage, cerebral infarction), deep vein thrombosis, or pulmonary embolism within 12 months before enrollment.

  • or untreated malignant tumors.
  • Major surgery or severe traumatic injuries, fractures, or ulcers within 4 weeks before enrollment.
  • Addictive habits such as drug abuse or alcoholism.
  • History of psychotropic drug abuse that is not controllable or presence of mental disorders, including major psychiatric illnesses (e.g., depression [BDI score >20], anxiety, obsessive-compulsive disorder, schizophrenia, autism, chronic sleep disorders, consciousness disorders).
  • Pregnant, breastfeeding, planning to conceive, or women of without reliable .
  • Participation in other clinical trials within the past month.
  • Cognitive impairments or poor compliance from subjects, family members, or caregivers, or inability to complete at least 12 months of follow-up and rehabilitation training.
  • Other conditions that increase the risk of study participation or device use, as determined by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Experimental
    BCI-SCS-EXO

    Participants will undergo a BCI-SCS-EXS intervention, involving implatation of high-density ECoG electrodes, as well as SCS electrodes. The system will be calibrated to synchronize BCI-decoded motor intent with SCS parameters and integrate with the exoskeleton (EXS) to provide synchronized gait assistance. Safety and efficacy assessments will be conducted at 1, 2, 3, 6, and 12 months post-intervention.

    Device: BCI-SCS-EXS

Interventions

  • DeviceBCI-SCS-EXS

    Participants will undergo a BCI-SCS-EXS intervention designed to enhance neurorehabilitation for spinal cord injury (SCI). The intervention includes: 1. BCI Implantation: High-density ECoG electrodes placed over the motor cortex to decode lower limb movement intent. 2. SCS Electrode Implantation: 5-6-5 paddle electrodes implanted at T11-L2 to deliver targeted spinal cord stimulation. 3. System Calibration: BCI-SCS synchronization to trigger stimulation parameters based on decoded motor intent. SCS-EXS integration to provide synchronized gait assistance. 4. Rehabilitation Training: Daily training sessions (60 minutes, 5 times/week for 1 year) combining BCI-SCS-EXS. 5. Follow-Up: Safety and efficacy assessments at 1, 2, 3, 6, and 12 months post-intervention. This intervention aims to promote neuroplasticity and functional recovery through brain-controlled spinal activation and synchronized exoskeleton assistance.

06

What researchers measure

Primary outcomes

  1. The content and number of AEs as well as their severity according to CTCAE v6.0

    The safety of the BCI-SCS-EXS system is evaluated by focusing on adverse events (AEs) associated with the trial devices (BCI, SCS, and EXS). AEs are documented and categorized according to their severity and relationship to the devices. The primary outcome measure calculated as the content and number of AEs as well as their severity according to CTCAE v6.0. This metric provides an overview of the safety profile of the BCI-SCS-EXS system.

    Time frame: 0-12 months post-implantation

Secondary outcomes

  1. Signal Acquisition Normal Rate of BCI

    Signal Acquisition Normal Rate is quantified as the ratio of successfully captured high-quality ECoG signal segments to the total number of predefined-length segments. This metric is calculated by analyzing the proportion of segments that meet predefined quality criteria as signal-to-noise ratio (SNR) \>10 dB. The rate is expressed as a percentage and reflects the reliability of the BCI system in capturing usable signals.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  2. Electrode Impedance of BCI electrodes

    Electrode impedance is measured to ensure optimal signal transmission. Impedance is assessed using an EEG acquisition system with a low-noise preamplifier and impedance detection software. The impedance value, expressed in kilohms (kΩ), reflects the resistance between the electrode and scalp.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  3. Effective Channel Count of BCI

    The effective channel count is quantified by the number of channels with a signal-to-noise ratio (SNR) exceeding 10 dB. SNR is calculated by analyzing the power spectral density of each channel. The count reflects the system's ability to reliably capture high-quality neural signals.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  4. Electrode Impedance Stability of SCS

    Electrode impedance stability is assessed by measuring the impedance of each SCS electrode channel at regular intervals. Impedance is measured using a calibrated impedance meter integrated with the SCS system. The stability is quantified by calculating the coefficient of variation (CV) of impedance values over time. A lower CV indicates more stable impedance.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  5. Position Stability of SCS

    Position stability is evaluated using X-ray imaging to confirm the placement of SCS electrodes relative to the T12 vertebral body. Stability is quantified by comparing the initial position with subsequent measurements over time. A positional shift greater than 2 mm is considered significant, indicating potential instability.

    Time frame: 0, 3, 6, 12 months post-implantation

  6. Battery Fault Rate of SCS

    The battery fault rate is quantified by recording the number of unexpected battery failures or shutdowns during the study period. This metric is calculated as the total count of such events divided by the total number of battery operation days. The rate is expressed as a percentage to reflect the reliability of the SCS system's power supply over time.

    Time frame: 0-12 months post-implantation

  7. Command Trigger Success Rate of BCI-SCS Matching

    The command trigger success rate is quantified as the percentage of BCI commands that successfully activate the SCS system. This is calculated as dividing the number of successful triggers by the total number of BCI commands issued during 5 minutes. The rate is expressed as a percentage, with higher values indicating more reliable BCI-SCS synchronization.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  8. Delay Drift Deviation of BCI-SCS Matching

    The delay drift deviation is quantified by measuring the temporal deviation of the actual delay between BCI command issuance and SCS response from the intended delay. This deviation is calculated as the average difference in milliseconds over a 5-minute trial. Lower values indicate more precise synchronization between the BCI and SCS systems.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  9. Recognition Accuracy of BCI Brain Signal Decoding

    The recognition accuracy is quantified through offline analysis using confusion matrices to evaluate the precision of movement intent decoding. Accuracy is calculated as the ratio of correctly decoded commands to the total number of commands analyzed, expressed as a percentage. Higher accuracy values indicate more reliable BCI signal decoding.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  10. Latency of BCI Brain Signal Decoding

    The latency is quantified as the time interval from the acquisition of ECoG signals to the generation of control commands. This is measured in milliseconds using timestamp synchronization between signal capture and command output. Lower latency values indicate more efficient real-time decoding performance of the BCI system.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  11. Gait Trigger Delay of SCS-EXS Matching

    The gait trigger delay is quantified as the time interval from the initiation of an SCS pulse to the commencement of exoskeleton joint movement. This delay is measured using synchronized data logging from both the SCS device and the exoskeleton's motion sensors, with the time difference calculated in milliseconds. Lower values indicate more precise synchronization between spinal cord stimulation and exoskeleton-assisted gait.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  12. Joint Movement Consistency of SCS-EXS Matching

    The joint movement consistency is quantified by measuring the correlation between hip/knee/ankle joint movements and SCS stimulation pulses using Pearson correlation coefficients. Joint movements are captured via motion sensors, while SCS pulses are logged by the stimulation device. The Pearson coefficient is calculated for each joint, with values closer to +1 or -1 indicating stronger consistency between joint movement and stimulation timing.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  13. Lower Limb Motor Score (LEMS)

    The LEMS quantifies motor function recovery of key muscle groups in the lower limbs by assessing muscle strength on a scale from 0 (no movement) to 5 (normal strength) for each muscle group. The total score is calculated by summing the individual muscle scores of iliopsoas, quadriceps femoris, and tibialis anterior muscles, with higher scores indicating better motor function recovery.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  14. Muscle Strength of Lower Limbs

    Muscle strength is assessed using the Medical Research Council (MRC) grading scale for the iliopsoas, quadriceps femoris, gastrocnemius, and tibialis anterior muscles. The MRC scale ranges from 0 to 5, with 0 indicating no muscle contraction and 5 indicating normal strength. Each muscle group is evaluated individually, and the scores are recorded to quantify the strength of each muscle. Higher MRC grades indicate better muscle function.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  15. Assisted Standing Time

    Assisted standing time is quantified as the duration patients can stand independently with exoskeleton assistance. This is measured in seconds using a stopwatch or timing software. The assessment is conducted in a standardized environment to ensure consistency. Longer durations indicate improved standing endurance and stability.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  16. 10-Meter Walk Test (10MWT)

    The 10MWT measures walking or assisted walking speed over a 10-meter distance. Walking speed is calculated by timing the duration it takes for a patient to walk 10 meters at their comfortable pace. The speed is then expressed in meters per second (m/s). Higher walking speeds indicate better mobility and functional recovery.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  17. Gait Step Length

    These metrics are captured using motion analysis systems. Step length is measured in centimeters during 10MWT. Higher step length indicate improved walking function.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  18. Gait Joint Range

    These metrics are captured using motion analysis systems. Joint range of motion is measured in degrees during 10MWT. Higher joint range of motion indicate improved walking function.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  19. Gait Symmetry

    These metrics are captured using motion analysis systems. Gait Symmetry is measured during 10MWT by comparing the consistency of steps between limbs. More symmetrical gait patterns, indicate improved walking function.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  20. Surface Electromyography (sEMG)

    sEMG measures resting and task-specific muscle activity during leg and knee extension. Muscle activity is captured using surface electrodes placed over target muscles, with signals recorded in microvolts (µV). Activity is quantified by calculating the root mean square (RMS) of the signal over a defined period. Higher RMS values indicate greater muscle activation during specific tasks.

    Time frame: Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  21. Nerve Conduction Velocity

    Nerve conduction velocity is quantified via EMG to assess the efficiency of neural signal transmission in limb muscles. This involves stimulating specific nerves and recording the resulting muscle action potentials. The conduction velocity is calculated by measuring the distance between the stimulation point and the recording electrode, divided by the latency of the evoked response, expressed in meters per second (m/s). Higher values indicate more efficient nerve conduction.

    Time frame: 0, 6, 12 months post-implantation

  22. Urodynamics

    Urodynamics is quantified by measuring bladder residual volume and maximum free urine flow rate. Bladder residual volume is assessed using ultrasound or catheterization, expressed in milliliters (mL). Maximum free urine flow rate is measured during spontaneous voiding, expressed in milliliters per second (mL/s). These parameters provide insights into bladder function and urinary tract efficiency.

    Time frame: 0, 6, 12 months post-implantation

  23. SF-36 Health Survey

    The SF-36 Health Survey quantifies physical and mental health-related quality of life through a standardized questionnaire. This survey includes multiple domains such as physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored on a scale from 0 to 100, with higher scores indicating better health status and quality of life.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  24. SCI-QOL Psychological Adaptation Subscale

    The SCI-QOL Psychological Adaptation Subscale quantifies psychological adaptation to spinal cord injury (SCI) through a series of Likert-scale items. This subscale assesses various aspects of psychological well-being, including emotional well-being, depression, anxiety, stigma, grief/loss, self-evaluation, and psychological trauma. Each item is scored on a scale from 1 to 5, with higher scores indicating better psychological adaptation and mental health.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  25. Cognitive Function by MMSE

    The Mini-Mental State Examination (MMSE) evaluates orientation, registration, attention, recall, and language, with scores ranging from 0 to 30, where higher scores indicate better cognitive function.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  26. Cognitive Function by MoCA

    The Montreal Cognitive Assessment (MoCA) assesses a broader range of cognitive domains, including attention, executive function, memory, language, visuospatial abilities, and abstraction, with scores ranging from 0 to 30. Higher scores on both tests indicate better cognitive performance.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  27. Pain Intensity

    Pain intensity is quantified using the Visual Analog Scale (VAS). Patients are asked to rate their pain on a continuous scale from 0 to 10, where 0 represents no pain and 10 represents the worst possible pain. The score is recorded in numerical values, with lower scores indicating less pain intensity.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

  28. Psychosocial Impact of Assistive Devices

    The psychosocial impact of assistive devices is evaluated using the Psychosocial Impact of Assistive Devices Scale (PIADS). This scale assesses the influence of assistive devices on an individual's competence, adaptability, and self-esteem. Each domain is scored on a scale from -3 to +3, with higher positive scores indicating a more favorable impact on psychosocial well-being.

    Time frame: 0, 1, 2, 3, 6, 12 months post-implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gad P, Gerasimenko Y, Zdunowski S, Turner A, Sayenko D, Lu DC, Edgerton VR. Weight Bearing Over-ground Stepping in an Exoskeleton with Non-invasive Spinal Cord Neuromodulation after Motor Complete Paraplegia. Front Neurosci. 2017 Jun 8;11:333. doi: 10.3389/fnins.2017.00333. eCollection 2017. PubMed 28642680 ↗
  • Gorgey AS, Gill S, Holman ME, Davis JC, Atri R, Bai O, Goetz L, Lester DL, Trainer R, Lavis TD. The feasibility of using exoskeletal-assisted walking with epidural stimulation: a case report study. Ann Clin Transl Neurol. 2020 Feb;7(2):259-265. doi: 10.1002/acn3.50983. Epub 2020 Feb 5. PubMed 32023011 ↗
  • Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7. PubMed 35132264 ↗
  • Lorach H, Galvez A, Spagnolo V, Martel F, Karakas S, Intering N, Vat M, Faivre O, Harte C, Komi S, Ravier J, Collin T, Coquoz L, Sakr I, Baaklini E, Hernandez-Charpak SD, Dumont G, Buschman R, Buse N, Denison T, van Nes I, Asboth L, Watrin A, Struber L, Sauter-Starace F, Langar L, Auboiroux V, Carda S, Chabardes S, Aksenova T, Demesmaeker R, Charvet G, Bloch J, Courtine G. Walking naturally after spinal cord injury using a brain-spine interface. Nature. 2023 Jun;618(7963):126-133. doi: 10.1038/s41586-023-06094-5. Epub 2023 May 24. PubMed 37225984 ↗
  • Liu P, Cheng Y, Xu Z, Li X, Chen Z, Duan W. Spatiotemporal spinal cord stimulation with real-time triggering exoskeleton restores walking capability: a case report. Ann Clin Transl Neurol. 2025 Mar;12(3):659-665. doi: 10.1002/acn3.52281. Epub 2024 Dec 15. PubMed 39675019 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to the inclusion of proprietary and commercially sensitive information related to the development and operation of the BCI-SCS-EXS system. The data contain technical specifications, algorithmic details, and performance metrics that are protected as intellectual property by the collaborating research institutions and industry partners. Sharing such data could compromise competitive advantages, hinder future innovation, and violate confidentiality agreements. However, aggregated and anonymized results will be made available upon reasonable request for scientific and regulatory purposes, ensuring transparency while safeguarding commercial interests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 12 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2025
First posted
Apr 23, 2025
StartActual
Apr 23, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
Apr 30, 2027
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939660
Collaborators
Beijing Xinzhida Neural Technology Co., Ltd, Beijing Pins Medical Co., Ltd, Hangzhou RoboCT Technology Development Co.,Ltd
Responsible party
Wanru Duan (Chief physician, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Apr 23, 2025
Start date
Apr 23, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
May 20, 2025

Study contacts

Penghao Liu, Doctor
Contact
liuph14@hotmail.com
+86-17604300002

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion